Annual report
Reg. 34 (1) Annual Report. 9 Sep
Source: Bse
Senores Pharmaceuticals Limited (SENORES)
Small CapPharma stocks · Small cap · NSE
Senores Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result27 Jul, 09:01 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
66BullishSMA20 -8.0% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 44
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SENORESD candles · FIT view+40.7%Latest close ₹1253.60 on 2026-10-19
Bar
-5.3%
RSI
37
MACD hist
-6.84
52W pos
61%
2026-10-19O ₹1323.60H ₹1345.00L ₹1241.30C ₹1253.60Vol 2.5L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SENORESNifty PharmaNifty 500
- SENORES
- -9.5%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -3.9 pp
Chart stats
19 Oct 2026- From 52W high
- -21.6%
- 52W range position
- 61%
- ATR (14)
- 4.7%
- Volume vs 20D
- 1.06x
- Avg traded value
- ₹31.1 Cr
- 20D price channel
- ₹1,241.3 - ₹1,435
₹1,599
₹705.1 - ₹1,599
₹59.5
Latest completed session
20-session average
42.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST35
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +30.4% · PAT +42.9% YoY
Technical
Bullish66
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence72
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +30% YoY · PAT +43% YoY · margin expansion · operating leverage
Filed 27 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹180 Cr | +30.4% | +2.9% |
| EBITDA | ₹54 Cr | +58.8% | +14.9% |
| Operating margin | 30.0% | +500 bps | +300 bps |
| PAT | ₹30 Cr | +42.9% | -18.9% |
| PAT margin | 16.7% | +145 bps | -447 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 48.20
- P/B
- 6.51
- EV/EBITDA
- 27.23
- Market Cap
- 6085.00Cr
Profitability
- ROE
- 13.40%
- ROCE
- 15.10%
- ROA
- 8.17%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 14.00%
- EPS 5Y
- 14.00%
- Revenue 3Y
- 28.00%
- EPS 3Y
- 35.00%
Balance Sheet
- Debt/Equity
- 0.37
- Interest Coverage
- 7.44×
- Altman Z
- 7.28
- Book Value
- 203.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 62.00 Cr
- EPS TTM
- 27.43
Shareholding
- Promoter Hold
- 45.82%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 69%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 633+59.0% vs prev
Net Profit
₹ CrLatest: 122+110.3% vs prev
Return on Equity
%Latest: 13.1+77.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 37.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~8.7% over last month) — short-term momentum negative.
- RSI(14) at 37 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 22% off 52W high · 78% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
88
RS percentile
Stage 2 UptrendEstablished S2
1M return
-10.6%
3M return
-9.5%
6M return
+42.1%
1Y return
+59.9%
RS 1D
-1
RS 20D
-5
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 4.0% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +6.9%.
50-DMA
price below
200-DMA
price above
S2 entered
09 Apr 2026
S2 age
136 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 191.77-3.93%
RS vs Nifty 500192
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth14/25
Quality7/20
Balance Sheet8/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
35
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
35/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Growth contributes 14/25 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Fair-value margin of safety is negative at -1.6%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
48.2
PB
6.5
EV/EBITDA
27.2
ROE
13.4%
ROCE
15.1%
FCF Yield
—
Debt/Equity
0.4
MoS
-1.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
35
Previous: 35
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-1.6%
Previous: -1.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
35
35
35
35
35
35
35
35
35
35
35
35
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹353.96
-254.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,234.35
-1.6% MoS
PEG
2.15
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 171
33
320.0
1.5%
-846%
WATCHLIST
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 169
35
43.7
14.3%
-27%
WATCHLIST
KPL
Small
Kwality Pharmaceuticals Limited
Healthcare Services
match 167
54
46.3
22.6%
+4%
FAIR VALUE
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 166
46
113.0
22.2%
-146%
FAIR VALUE
MOREPENLAB
Small
Morepen Laboratories Limited
Healthcare Services
match 165
20
63.1
5.3%
-1007%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Senores Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
72Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 69th percentile of the scored universe and 58th percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
36 docs text-extracted · 12 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
69th percentile
overall median 67 · Pharma: 58th pctile, median 70 · Small: 71st pctile, median 66
Evidence depth
Financial-only
36 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
87
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸4/4 latest quarters had positive YoY PAT growth.
- ▸Latest 3 quarters had positive YoY PAT growth.
Trust risks
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Senores Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - We are enclosing herewith the Newspaper Publication for the 9th Annual General Meeting of the Company.
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 Aug - Senores Pharmaceuticals Limited has informed regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25, 2026
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Senores Pharmaceuticals Limited has informed regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15 P.M. (IST)
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Jul - Senores Pharmaceuticals Limited has informed regarding Analyst/Institutional Investor meet scheduled to be held on July 07, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Jul - Senores Pharmaceuticals Limited has informed regarding copy of Newspaper Publication
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Jun - Senores Pharmaceuticals to attend Choice Broking virtual group investor meeting on 12 June 2026, 3:00-4:00 PM IST.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 10 Jun - Company Secretary and Compliance Officer Vinay Kumar Mishra relieved from June 10, 2026; KMPs authorized for disclosures.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Jun - Senores Pharmaceuticals Limited has informed regarding Analyst/Institutional Investor meet scheduled to be held on June 09, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 10 Jun - Company Secretary Vinay Kumar Mishra relieved effective June 10, 2026; KMPs authorised for disclosures.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.